Matches in DBpedia 2016-04 for { ?s ?p "Cannabidivarin (CBDV) is a non-psychoactive cannabinoid found in Cannabis. It is a homolog of cannabidiol (CBD), with the side-chain shortened by two methylene bridges (CH2 units). Plants with relatively high levels of CBDV have been reported in feral populations of C. indica ( = C. sativa ssp. indica var. kafiristanica) from northwest India, and in hashish from Nepal. CBDV has anticonvulsant effects.Similarly to CBD, it has 7 double bond isomers and 30 stereoisomers (see: Cannabidiol#Double bond isomers and their stereoisomers). It is not scheduled by Convention on Psychotropic Substances. It is being actively developed by GW Pharmaceuticals (as GWP42006)because of a demonstrated neurochemical pathway for previously-observed anti-epileptic and anti-convulsive action. GW has begun a phase 2 trial for adult epilepsy, and is to begin trials of this CBDV product in children in 2016 in Australia."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Cannabidivarin abstract "Cannabidivarin (CBDV) is a non-psychoactive cannabinoid found in Cannabis. It is a homolog of cannabidiol (CBD), with the side-chain shortened by two methylene bridges (CH2 units). Plants with relatively high levels of CBDV have been reported in feral populations of C. indica ( = C. sativa ssp. indica var. kafiristanica) from northwest India, and in hashish from Nepal. CBDV has anticonvulsant effects.Similarly to CBD, it has 7 double bond isomers and 30 stereoisomers (see: Cannabidiol#Double bond isomers and their stereoisomers). It is not scheduled by Convention on Psychotropic Substances. It is being actively developed by GW Pharmaceuticals (as GWP42006)because of a demonstrated neurochemical pathway for previously-observed anti-epileptic and anti-convulsive action. GW has begun a phase 2 trial for adult epilepsy, and is to begin trials of this CBDV product in children in 2016 in Australia.".
- Q1104117 abstract "Cannabidivarin (CBDV) is a non-psychoactive cannabinoid found in Cannabis. It is a homolog of cannabidiol (CBD), with the side-chain shortened by two methylene bridges (CH2 units). Plants with relatively high levels of CBDV have been reported in feral populations of C. indica ( = C. sativa ssp. indica var. kafiristanica) from northwest India, and in hashish from Nepal. CBDV has anticonvulsant effects.Similarly to CBD, it has 7 double bond isomers and 30 stereoisomers (see: Cannabidiol#Double bond isomers and their stereoisomers). It is not scheduled by Convention on Psychotropic Substances. It is being actively developed by GW Pharmaceuticals (as GWP42006)because of a demonstrated neurochemical pathway for previously-observed anti-epileptic and anti-convulsive action. GW has begun a phase 2 trial for adult epilepsy, and is to begin trials of this CBDV product in children in 2016 in Australia.".